Home AstraZeneca

AstraZeneca

Looking to expand your partner network with leading companies like AstraZeneca? Consider joining Inpart's global network for free.

Stay informed about the latest news about AstraZeneca by subscribing to our newsletter.

What is AstraZeneca best known for?

AstraZeneca is best known for its contributions in the field of pharmaceuticals, particularly in areas like oncology, respiratory diseases, cardiovascular health, and immunology. The company has developed widely recognized medications such as Tagrisso, Symbicort, Crestor, and the COVID-19 vaccine, among others.

Where is AstraZeneca located?

AstraZeneca has its global headquarters located in Cambridge, England, United Kingdom. However, the company has multiple offices, research facilities, and manufacturing sites worldwide, spanning across Europe, North America, Asia, and other regions.

Got a news story for us related to AstraZeneca? Send it to us here.

Latest Posts

News and Trends 31 Mar 2025

AstraZeneca bets on Asia: a surge of deals in March amid fraud probe

AstraZeneca has vowed to spend over $10 billion in Asia, particularly in China, to build Beijing into an R&D hub amid probe into fraud scandals.

March 31, 2025 - 7 minutesmins - By Roohi Mariam Peter

More News! 23 Jul 2024

First AKT-targeting drug capivasertib to hit the market, could it open the door for more?

As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out!

July 23, 2024 - 7 minutesmins - By Jules Adam

News and Trends 21 Dec 2023

The big pharma race against deadly RSV steps up in 2023

GSK and Pfizer received FDA approval for their RSV vaccines in 2023. Now, AstraZeneca has joined the race with its latest acquisition.

December 21, 2023 - 7 minutesmins - By Roohi Mariam Peter

Opinion 1 Nov 2023

Could this be the start of a new era for PI3K drugs?

There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […]

November 1, 2023 - 7 minutesmins - By External Contributor

News and Trends 18 Jul 2023

FDA approves Beyfortus ahead of 2023-24 RSV season

The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […]

July 18, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy. […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2023

SandboxAQ launches new division to boost drug development

After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jun 2023

Quell in potential $2B AstraZeneca cell therapy deal

Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […]

June 9, 2023 - 3 minutesmins - By Jim Cornall

Podcast 26 May 2023

Beyond Biotech podcast 47

The companies Daiichi Sankyo and AstraZeneca have worked together for several years. This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca. On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining […]

May 26, 2023

News and Trends 4 May 2023

World’s first RSV vaccine for older adults gets FDA approval

GSK plc says the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. It is the first RSV vaccine for older adults to be approved anywhere in […]

May 4, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

AstraZeneca creates FRAGLER for DNA synthesis

“Plasmids are critical for so many processes in early drug discovery,” says David Öling, associate principal scientist at AstraZeneca. “From protein production, cell line engineering, CAR-T cell therapy, viral vector generation, therapeutic genome editing, mRNA/vaccine production and more. The time it takes and the cost of producing plasmids for DNA constructs is a critical limiting […]

February 2, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product

Ibex Medical Analytics has announced an agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry (IHC) scoring in breast cancer patients. Scoring of HER2 (human epidermal growth factor receptor 2) protein expression in breast […]

January 26, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

AstraZeneca

What is AstraZeneca best known for?

Where is AstraZeneca located?

AstraZeneca bets on Asia: a surge of deals in March amid fraud probe

First AKT-targeting drug capivasertib to hit the market, could it open the door for more?

The big pharma race against deadly RSV steps up in 2023

Could this be the start of a new era for PI3K drugs?

FDA approves Beyfortus ahead of 2023-24 RSV season

AstraZeneca non-small cell lung cancer drug meets primary endpoint

SandboxAQ launches new division to boost drug development

Quell in potential $2B AstraZeneca cell therapy deal

Beyond Biotech podcast 47

World’s first RSV vaccine for older adults gets FDA approval

AstraZeneca creates FRAGLER for DNA synthesis

Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!